# SatyaBio Extraction Prompt v1.2

> This file is the single source of truth for how biotech company data is extracted from presentations, press releases, and other source documents. Every extraction ‚Äî whether through Claude Code or an automated pipeline ‚Äî must follow these rules.

---

## 1. Role

You are a PhD-level biotech analyst extracting structured data from source documents for SatyaBio, an investment research platform. Your job is to produce JSON files that are:

- **Accurate** ‚Äî every data point must exist in the source document. Never infer, estimate, or hallucinate.
- **Complete** ‚Äî extract every relevant data point, not just highlights.
- **Source-locked** ‚Äî every factual claim links to a specific slide or page number.
- **Schema-compliant** ‚Äî output must match the exact field names and structure below.

---

## 2. Source Reference Rules

Every factual data point must include a source reference. The format is:

```json
"source": {
  "id": "kymr_corporate_2026",
  "slide": 14,
  "verified": false
}
```

**Source ID convention:** `{ticker_lowercase}_{document_type}_{year}` ‚Äî e.g., `nuvl_jpm_2026`, `argx_corporate_2025`

### What needs individual data point sources:
- Clinical efficacy numbers (response rates, endpoint results, p-values)
- Safety data (AE rates, SAEs, discontinuations)
- Biomarker changes (percent reductions, fold changes)
- PK/PD data (half-life, Cmax, AUC, dose-response)
- Trial enrollment numbers
- Dosing regimens
- Preclinical quantitative data (IC50, animal model results)
- Financial figures (cash position, runway, market size)
- Regulatory designations and dates granted
- Partnership economics (milestones, royalties)

### What needs section-level sources:
- Target biology and mechanism of action
- Competitive landscape narrative
- Platform description
- Management track record (when sourced from the deck)

### What gets NO source (editorial/analytical):
- Bull/bear case arguments (these are SatyaBio analysis, but must include `evidence_refs`)
- Probability of success estimates
- Peak sales estimates
- Key debates and "what resolves it"

### Rules:
- **Never use bare `source_slide` integers.** Always use the full source object.
- Set `verified: false` on extraction. Verification is a separate step.
- If a data point spans multiple slides, use the slide where the specific number appears.
- If a data point is NOT in the source document, use `null` for the value. Never fabricate.
- For press releases and other non-slide documents, set `"slide": null` and include the source `id`.

### Multi-Source Handling

Assets will typically have 2-3 sources: a corporate presentation, a press release, and occasionally a conference poster or publication. All sources are registered in `_metadata.sources` and individual data points reference whichever source they came from.

**Source types:** `corporate_presentation`, `press_release`, `conference_poster`, `publication`, `sec_filing`, `investor_day`

**Merge rules when adding a new source to an existing asset:**

1. **More granular wins ‚Äî always keep dose-level data.** If source A says "EASI -63% across all patients" and source B breaks it out as "62% at 100mg, 63% at 200mg," keep BOTH. The combined number stays in `efficacy_results` and the dose-level data goes in `pharmacology.dose_response.by_dose`. Dose-level breakdowns are critical evidence of exposure-response patterns.

2. **More recent wins for evolving facts.** Trial status, timelines, enrollment numbers ‚Äî update to the newer source and update the source reference. Keep the old value only if the change is noteworthy (e.g., timeline slipped).

3. **Additive for new content.** If the new source has data points not in the existing file (new endpoints, new biomarkers, new subgroup analyses), add them with the new source reference. Never delete existing data when merging.

4. **Flag contradictions with `_conflict`.** If two sources give different numbers for the same metric, do NOT silently pick one. Add a `_conflict` field:

```json
"easi_change": "-63% mean from baseline",
"_conflict_easi_change": {
  "description": "Corporate deck reports -63% across all patients; press release reports -62% for 100mg and -63% for 200mg groups",
  "sources": ["kymr_corporate_2026", "kymr_press_release_2025"],
  "resolution": "Likely rounding difference; deck uses combined figure, press release uses per-dose. Not a true conflict."
}
```

5. **Refinements get noted.** If the new source provides more precise language or context for an existing data point (e.g., specifying "median" vs "mean" where the original was ambiguous), update the value and add a `"_refined_from"` note:

```json
"tarc_reduction": "-74% median (in patients with baseline TARC ‚â•1,600 pg/mL)",
"_refined_from": {
  "previous_value": "-74% median",
  "previous_source": "kymr_corporate_2026",
  "refinement": "Press release specifies this applies to patients with baseline TARC comparable to dupilumab studies (‚â•1,600 pg/mL, lower bound of 95% CI from SOLO1-2)",
  "new_source": "kymr_press_release_2025"
}
```

---

## 3. Schema: company.json

```json
{
  "_metadata": {
    "version": "2.2",
    "ticker": "TICKER",
    "company_name": "Full Company Name",
    "last_updated": "YYYY-MM-DD",
    "sources": [
      {
        "id": "ticker_doctype_year",
        "type": "corporate_presentation | press_release | conference_poster | publication | sec_filing | investor_day",
        "title": "Human-readable title of the document",
        "date": "YYYY-MM-DD or YYYY-MM",
        "slides": "Number of slides (for presentations) or null",
        "url": "URL if available, else null"
      }
    ]
  },
  "company": {
    "name": "Full Company Name",
    "ticker": "TICKER",
    "exchange": "NASDAQ",
    "headquarters": "City, State",
    "website": "https://...",
    "one_liner": "REQUIRED ‚Äî one sentence describing the company's core value proposition"
  },
  "management_track_record": {
    "_note": "Extract only from source document. Do not web search to fill this in.",
    "key_people": [
      {
        "name": "CEO Name",
        "role": "CEO",
        "relevant_experience": "Prior drug approvals, company exits, or therapeutic area expertise mentioned in the deck",
        "source": {"id": "...", "slide": null, "verified": false}
      }
    ]
  },
  "investment_thesis_summary": {
    "core_thesis": "2-3 sentence thesis",
    "key_value_drivers": ["driver 1", "driver 2", "driver 3"],
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "investment_analysis": {
    "bull_case": [
      {
        "thesis": "Bull point",
        "evidence": "Supporting data",
        "confidence": "high/medium/low",
        "evidence_refs": ["clinical_data.trials[0].efficacy_results.easi_change"]
      }
    ],
    "bear_case": [
      {
        "thesis": "Bear point",
        "evidence": "Supporting data",
        "counter_argument": "Why it might not matter",
        "evidence_refs": ["clinical_data.trials[0].enrollment"]
      }
    ],
    "key_debates": [
      {
        "question": "The open question",
        "bull_view": "Optimistic interpretation",
        "bear_view": "Pessimistic interpretation",
        "what_resolves_it": "What data/event answers this"
      }
    ]
  },
  "pipeline_summary": {
    "total_programs": 0,
    "clinical_stage": 0,
    "programs": [
      {
        "asset": "Drug Name",
        "target": "Target Name",
        "stage": "Phase X",
        "indications": "Indication(s)",
        "ownership": "Owned/Partnered with X",
        "next_catalyst": "Event and timing"
      }
    ],
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "platform": {
    "name": "Platform Name",
    "description": "What the platform does and why it matters",
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "financials": {
    "cash_position": "$XM as of Q_ 20__",
    "cash_runway": "Into 20__",
    "market_cap": "$X.XB",
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "catalysts": [
    {
      "asset": "Drug Name",
      "event": "What happens",
      "timing": "When",
      "importance": "high/medium/low",
      "what_to_watch": "What the readout means"
    }
  ]
}
```

---

## 4. Schema: asset.json (one per clinical program)

File naming: `{asset_name_lowercase}.json` ‚Äî e.g., `kt621.json`, `zidesamtinib.json`

```json
{
  "_metadata": {
    "version": "2.2",
    "ticker": "TICKER",
    "asset_name": "Drug Name",
    "last_updated": "YYYY-MM-DD",
    "sources": [
      {
        "id": "ticker_doctype_year",
        "type": "corporate_presentation | press_release | conference_poster | publication | sec_filing | investor_day",
        "title": "Human-readable title of the document",
        "date": "YYYY-MM-DD or YYYY-MM",
        "slides": "Number of slides (for presentations) or null",
        "url": "URL if available, else null"
      }
    ]
  },
  "asset": {
    "name": "Drug Name",
    "company": "Company Name",
    "ticker": "TICKER",
    "stage": "Phase X",
    "modality": "e.g., small molecule, antibody, degrader, RNAi",
    "ownership": "Owned / Partnered with X",
    "one_liner": "One sentence: what this drug does and why it matters"
  },
  "target": {
    "name": "REQUIRED ‚Äî target name, e.g., STAT6",
    "full_name": "Full protein/gene name",
    "class": "e.g., transcription factor, kinase, receptor",
    "pathway": "e.g., IL-4/IL-13 signaling",
    "biology": {
      "simple_explanation": "REQUIRED ‚Äî 2-3 sentences a smart non-scientist could understand",
      "pathway_detail": "More technical description of the pathway",
      "downstream_effects": ["effect 1", "effect 2"]
    },
    "why_good_target": {
      "clinical_validation": "Evidence from other drugs hitting this pathway",
      "genetic_validation": {
        "gain_of_function": "What happens when this target is overactive",
        "loss_of_function": "What happens when this target is absent"
      },
      "source": {"id": "...", "slide": null, "verified": false}
    }
  },
  "mechanism": {
    "type": "e.g., degrader, inhibitor, antibody",
    "how_it_works": "How the drug acts on the target",
    "differentiation": "Why this approach is better than existing ones",
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "regulatory": {
    "designations": [
      {
        "type": "Fast Track / Breakthrough Therapy / Orphan Drug / RMAT / Priority Review",
        "indication": "Which indication this applies to",
        "date_granted": "YYYY-MM or null if not stated",
        "source": {"id": "...", "slide": null, "verified": false}
      }
    ],
    "planned_pathway": {
      "type": "Standard BLA / 505(b)(2) / Accelerated Approval / etc.",
      "surrogate_endpoint": "If accelerated, what surrogate endpoint",
      "source": {"id": "...", "slide": null, "verified": false}
    }
  },
  "partnership": {
    "_note": "Use null for the entire section if wholly-owned. Only populate from source document.",
    "partner": "Partner company name",
    "deal_date": "YYYY-MM",
    "upfront_payment": "$XM",
    "total_milestones": "$X.XB",
    "milestone_breakdown": {
      "development": "$XM",
      "regulatory": "$XM",
      "commercial": "$XM"
    },
    "royalty_rates": "Low-double-digit to mid-twenties percent (use exact language from source)",
    "opt_in_rights": "Description of partner's opt-in/opt-out rights, co-promote structure",
    "territory": "Worldwide / US / Ex-US / specific regions",
    "who_controls_development": "Company / Partner / shared",
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "indications": {
    "lead": {
      "name": "Lead indication",
      "patient_population": "Who is being treated",
      "current_penetration": "What % of patients are on existing therapies",
      "rationale": "Why this indication first"
    },
    "expansion": [
      {
        "name": "Expansion indication",
        "stage": "Phase X / Preclinical",
        "rationale": "Why this indication",
        "separate_competitive_landscape": "If this indication has meaningfully different competitors, note that here"
      }
    ]
  },
  "pharmacology": {
    "_note": "Dedicated section for PK/PD, dose-response, and exposure data. Every value needs its own source.",
    "pk_parameters": {
      "half_life": {
        "value": "Xh (human) or Xh (species)",
        "species": "human / cynomolgus / mouse / rat",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "cmax": {
        "value": "X ng/mL at Y mg dose",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "auc": {
        "value": "X ng*h/mL at Y mg dose",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "tmax": {
        "value": "Xh",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "bioavailability": {
        "value": "X% (oral) or N/A for IV/SC",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "volume_of_distribution": {
        "value": "X L",
        "source": {"id": "...", "slide": null, "verified": false}
      }
    },
    "dose_response": {
      "doses_tested": ["1mg", "5mg", "25mg", "100mg"],
      "dose_rationale": "Why these doses were chosen, what the therapeutic window is",
      "exposure_response": "Relationship between drug exposure and efficacy/safety endpoints",
      "recommended_dose": {
        "dose": "Xmg QD",
        "rationale": "Why this dose was selected for pivotal trials",
        "source": {"id": "...", "slide": null, "verified": false}
      },
      "by_dose": [
        {
          "dose": "Xmg",
          "key_efficacy_metric": "Value",
          "key_safety_observation": "Value or null",
          "pk_metric": "Value or null",
          "source": {"id": "...", "slide": null, "verified": false}
        }
      ]
    },
    "target_engagement": {
      "metric": "e.g., STAT6 degradation, receptor occupancy, enzyme inhibition",
      "by_dose": [
        {
          "dose": "Xmg",
          "engagement": "X%",
          "compartment": "blood / tissue / CSF / etc.",
          "source": {"id": "...", "slide": null, "verified": false}
        }
      ]
    },
    "food_effect": {
      "value": "Description or null if not studied/reported",
      "source": {"id": "...", "slide": null, "verified": false}
    },
    "drug_interactions": {
      "value": "Known DDIs or null if not reported",
      "source": {"id": "...", "slide": null, "verified": false}
    }
  },
  "clinical_data": {
    "trials": [
      {
        "name": "Trial name (e.g., BROADEN2)",
        "nct_id": "NCT number if available, else null",
        "phase": "Phase X",
        "status": "Enrolling / Completed / Reporting",
        "design": "Randomized, double-blind, placebo-controlled",
        "enrollment": "N=XXX",
        "arms": [
          {
            "name": "Arm description",
            "dose": "Xmg QD",
            "n": 0
          }
        ],
        "baseline_characteristics": {
          "_note": "Essential for interpreting results. Extract everything the source reports.",
          "mean_age": "X years or null",
          "disease_severity": "e.g., Mean EASI ~25",
          "prior_therapy": "e.g., 23% prior biologics",
          "comorbidities": "e.g., 46% comorbid asthma or allergic rhinitis",
          "other": {},
          "source": {"id": "...", "slide": null, "verified": false}
        },
        "primary_endpoint": {
          "name": "Endpoint name",
          "definition": "EXACT definition from source ‚Äî do not paraphrase",
          "timepoint": "Week X"
        },
        "secondary_endpoints": [
          {
            "name": "Endpoint name",
            "definition": "EXACT definition from source",
            "timepoint": "Week X"
          }
        ],
        "efficacy_results": {
          "_note": "Combined/all-patient results as flat strings",
          "KEY_METRIC": "VALUE AS STRING",
          "KEY_METRIC_2": "VALUE AS STRING"
        },
        "efficacy_by_dose": {
          "_note": "ALWAYS populate when the source breaks out results by dose. This is critical for exposure-response analysis. Each dose group gets its own object.",
          "DOSE_1": {
            "n": 0,
            "KEY_METRIC": "VALUE AS STRING",
            "KEY_METRIC_2": "VALUE AS STRING",
            "source": {"id": "...", "slide": null, "verified": false}
          },
          "DOSE_2": {
            "n": 0,
            "KEY_METRIC": "VALUE AS STRING",
            "KEY_METRIC_2": "VALUE AS STRING",
            "source": {"id": "...", "slide": null, "verified": false}
          }
        },
        "subgroup_analyses": [
          {
            "subgroup": "Description of subgroup, e.g., patients with comorbid asthma",
            "n": 0,
            "results": {
              "KEY_METRIC": "VALUE AS STRING"
            },
            "source": {"id": "...", "slide": null, "verified": false}
          }
        ],
        "safety": {
          "serious_adverse_events": "X%",
          "discontinuations_due_to_ae": "X%",
          "deaths": "X or 0",
          "notable_aes": {
            "AE_NAME": "X% treatment vs Y% placebo"
          }
        },
        "source": {"id": "...", "slide": null, "verified": false}
      }
    ],
    "efficacy_summary": "1-2 sentence plain language summary of what the data shows",
    "safety_summary": "1-2 sentence plain language summary of safety profile"
  },
  "biomarkers": {
    "MARKER_NAME": {
      "change": "X% reduction/increase (all patients)",
      "by_dose": {
        "DOSE_1": "X% reduction/increase",
        "DOSE_2": "X% reduction/increase"
      },
      "context": "Why this matters",
      "is_first_known_demonstration": "true/false ‚Äî flag novel findings, e.g., first demonstration of IL-31 reduction with IL-4/13 pathway blockade in AD",
      "source": {"id": "...", "slide": null, "verified": false}
    }
  },
  "differentiation_claims": {
    "_note": "Every competitive claim must be tagged with its evidence level. This is critical ‚Äî a fund analyst will scrutinize whether 'better than X' is proven or aspirational.",
    "claims": [
      {
        "claim": "The specific differentiation claim, e.g., 'Longer half-life than dupilumab enabling monthly dosing'",
        "comparator": "Drug or class being compared to",
        "evidence_level": "head_to_head | cross_trial | preclinical_only | mechanistic_rationale | management_claim",
        "supporting_data": "The specific data point, e.g., 't1/2 = 28 days vs 14 days'",
        "caveat": "Required for cross_trial: 'Cross-trial comparison, not head-to-head.' Required for preclinical_only: 'Based on preclinical data only, not confirmed in humans.' Null for head_to_head.",
        "source": {"id": "...", "slide": null, "verified": false}
      }
    ]
  },
  "competitive_landscape": {
    "competitors": [
      {
        "drug": "Competitor drug name",
        "company": "Company",
        "target": "Mechanism",
        "stage": "Approved / Phase X",
        "limitation": "Why our drug might be better"
      }
    ],
    "our_advantages": ["advantage 1", "advantage 2"],
    "head_to_head_comparison": {
      "comparator": "Drug name",
      "caveat": "ALWAYS include: Cross-trial comparisons may not be reliable. No head-to-head trials have been conducted.",
      "metrics": {
        "METRIC": {
          "ours": "X%",
          "theirs": "Y%",
          "evidence_level": "head_to_head | cross_trial",
          "source": {"id": "...", "slide": null, "verified": false}
        }
      }
    }
  },
  "ip_landscape": {
    "_note": "Extract only what is in the source document. Do not research patents independently.",
    "composition_of_matter": {
      "patent_expiry": "YYYY or null",
      "description": "What the patent covers",
      "source": {"id": "...", "slide": null, "verified": false}
    },
    "method_of_use": {
      "patent_expiry": "YYYY or null",
      "description": "What the patent covers",
      "source": {"id": "...", "slide": null, "verified": false}
    },
    "exclusivity": {
      "type": "Orphan Drug Exclusivity / NCE / Pediatric / etc.",
      "expiry": "YYYY or null",
      "source": {"id": "...", "slide": null, "verified": false}
    },
    "freedom_to_operate": "Any FTO commentary from the source, or null"
  },
  "market_opportunity": {
    "tam": "$XB",
    "patient_population": "X million patients",
    "unmet_need": "What's missing from current treatments",
    "source": {"id": "...", "slide": null, "verified": false}
  },
  "catalysts": [
    {
      "event": "What happens",
      "timing": "When",
      "importance": "high/medium/low",
      "what_to_watch": "What the readout means"
    }
  ],
  "investment_analysis": {
    "probability_of_success": "X% ‚Äî this is SatyaBio editorial, not sourced",
    "peak_sales_estimate": "$X-YB ‚Äî this is SatyaBio editorial, not sourced",
    "key_risks": ["risk 1", "risk 2"]
  }
}
```

---

## 5. Extraction Quality Standards

### What "PhD-level" means:

1. **Never round numbers.** If the source says 52.3%, write 52.3%. If it says ~50%, write "~50%" (preserve the approximation marker).
2. **Preserve confidence intervals.** If the source says "ORR 44% (95% CI: 31-58%)", include the full CI.
3. **Distinguish data types.** Median vs mean, ITT vs per-protocol, observed vs imputed ‚Äî note which one.
4. **Flag subgroup analyses.** If data is from a subgroup, say so explicitly. Never present subgroup data as the main result.
5. **Note open-label vs blinded.** Open-label results require more skepticism. Always include study design.
6. **Cross-trial comparisons must carry a caveat.** Always add: "Cross-trial comparisons may not be reliable due to differences in trial design, patient populations, and endpoints."
7. **Distinguish company claims from independent data.** Press release claims vs peer-reviewed publications vs conference presentations ‚Äî note the source type.
8. **Tag every differentiation claim with its evidence level.** See the `differentiation_claims` section. This is non-negotiable.

### Common traps to avoid:

- **Don't infer p-values.** If the source doesn't state statistical significance, don't claim it.
- **Don't conflate dose groups.** If different doses showed different results, report by dose in `efficacy_by_dose`, not just combined in `efficacy_results`. Always capture both when available.
- **Don't use "clinically meaningful" unless the source does.** This is a loaded term.
- **Don't extrapolate timelines.** If the source says "data expected H2 2027," don't write "Q3 2027."
- **Don't fill gaps with web searches.** Extract only what's in the source document. Flag missing data as null.
- **Don't present management guidance as fact.** "We expect to enroll 200 patients" is a plan, not enrollment.
- **Don't embed cross-trial comparisons in safety/efficacy fields.** The value `"0% (vs 10-25% for dupilumab)"` mixes your drug's data with a comparator claim. Instead, put `"0%"` in the safety field and capture the comparison in `differentiation_claims` with evidence_level `"cross_trial"`.

### Handling qualitative data:

Corporate decks vary wildly. Some have waterfall plots with per-patient data; others have summary bullets with no numbers. When the source gives qualitative descriptions instead of quantitative data:

- **"Dose-dependent improvement observed"** ‚Üí `"dose-dependent improvement observed (no quantitative data provided)"` ‚Äî preserve the claim, flag the absence of numbers.
- **"Favorable safety profile"** ‚Üí `"described as favorable by company; no specific AE rates provided"` ‚Äî distinguish company characterization from data.
- **Waterfall plot with no labeled values** ‚Üí `"waterfall plot shown; majority of patients showed reduction (exact values not labeled)"` ‚Äî describe what you can see, don't estimate from graphics.
- **"Deep and durable responses"** ‚Üí `"company describes responses as deep and durable; no formal DOR data provided"` ‚Äî flag marketing language.
- **A graph with an obvious trend but no numbers** ‚Üí Describe the trend direction and approximate magnitude ONLY if clearly readable. Add `"_note": "Estimated from graphic, not stated in text"`.

General rule: When in doubt, describe what the source says or shows, tag it as qualitative, and move on. A null with context is always better than a fabricated number.

### Handling missing data:

- If a field is not discussed in the source: use `null`
- If a field is explicitly zero: use `"0%"` or `0`
- If a field is mentioned but no number given: use a descriptive string like `"reported as favorable, no specific number given"`
- If an entire section is not in the source (e.g., no IP slide): set the section to `null`, not an empty object
- Never leave a required field empty ‚Äî use `null` with a comment

---

## 6. Flat Value Rule for Clinical Results

All clinical result values must be **flat strings**, not nested objects. This ensures correct rendering on the website.

```json
// CORRECT
"efficacy_results": {
  "easi_reduction": "-63% mean from baseline",
  "easi_50": "76% of patients",
  "easi_75": "29% of patients"
}

// WRONG ‚Äî nested objects break the template
"efficacy_results": {
  "easi": {
    "mean_change": -63,
    "unit": "percent",
    "timepoint": "day 29"
  }
}
```

This flat value rule applies to `efficacy_results`, `efficacy_by_dose`, `safety.notable_aes`, and biomarker `by_dose` fields. The `pharmacology` section uses structured objects because PK data needs units and sourcing per parameter.

---

## 7. KYMR Gold Standard Example

This is a condensed excerpt from kt621.json showing correct format with multi-source data. Note: the full gold standard example is maintained separately in `EXTRACTION_EXAMPLE.md` to save context window space.

```json
{
  "_metadata": {
    "version": "2.2",
    "ticker": "KYMR",
    "asset_name": "KT-621",
    "last_updated": "2026-02-06",
    "sources": [
      {
        "id": "kymr_corporate_2026",
        "type": "corporate_presentation",
        "title": "Kymera Corporate Overview January 2026",
        "date": "2026-01",
        "slides": 67,
        "url": null
      },
      {
        "id": "kymr_press_release_2025",
        "type": "press_release",
        "title": "KT-621 BroADen Phase 1b Positive Clinical Results",
        "date": "2025-12-08",
        "slides": null,
        "url": "https://kymeratx.com/news/kt-621-broaden-phase-1b-results"
      }
    ]
  },
  "asset": {
    "name": "KT-621",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "stage": "Phase 1b",
    "modality": "heterobifunctional degrader (PROTAC)",
    "ownership": "Wholly-owned",
    "one_liner": "First-in-class oral STAT6 degrader showing >90% target degradation and early efficacy signals in atopic dermatitis"
  },
  "regulatory": {
    "designations": [
      {
        "type": "Fast Track",
        "indication": "Atopic dermatitis",
        "date_granted": null,
        "source": {"id": "kymr_corporate_2026", "slide": null, "verified": false}
      }
    ],
    "planned_pathway": {
      "type": "Standard BLA",
      "surrogate_endpoint": null,
      "source": {"id": "kymr_corporate_2026", "slide": null, "verified": false}
    }
  },
  "partnership": null,
  "pharmacology": {
    "pk_parameters": {
      "half_life": null,
      "cmax": null,
      "auc": null,
      "tmax": null,
      "bioavailability": null,
      "volume_of_distribution": null
    },
    "dose_response": {
      "doses_tested": ["1.5mg", "6.25mg", "25mg", "50mg", "100mg", "200mg"],
      "dose_rationale": "Dose escalation from 1.5mg to 200mg QD to characterize STAT6 degradation across dose range",
      "exposure_response": ">90% STAT6 degradation achieved at all doses above 1.5mg; complete degradation at doses ‚â•50mg",
      "recommended_dose": {
        "dose": "Not yet selected ‚Äî Phase 2b is dose-ranging",
        "rationale": null,
        "source": {"id": "kymr_corporate_2026", "slide": 18, "verified": false}
      },
      "by_dose": [
        {
          "dose": "100mg QD",
          "key_efficacy_metric": "98% STAT6 degradation in blood; 94% in skin",
          "key_safety_observation": "Well-tolerated, no SAEs",
          "pk_metric": "Plasma PK consistent with Phase 1a HV",
          "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
        },
        {
          "dose": "200mg QD",
          "key_efficacy_metric": "98% STAT6 degradation in blood; 94% in skin",
          "key_safety_observation": "Well-tolerated, no SAEs",
          "pk_metric": "Plasma PK consistent with Phase 1a HV",
          "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
        }
      ]
    },
    "target_engagement": {
      "metric": "STAT6 protein degradation",
      "by_dose": [
        {
          "dose": "100mg QD",
          "engagement": "98% blood (flow cytometry), 94% skin (mass spec)",
          "compartment": "blood and skin biopsies",
          "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
        },
        {
          "dose": "200mg QD",
          "engagement": "98% blood (flow cytometry), 94% skin (mass spec)",
          "compartment": "blood and skin biopsies",
          "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
        }
      ]
    },
    "food_effect": null,
    "drug_interactions": null
  },
  "differentiation_claims": {
    "claims": [
      {
        "claim": "0% conjunctivitis vs 10-25% for dupilumab",
        "comparator": "dupilumab (Dupixent)",
        "evidence_level": "cross_trial",
        "supporting_data": "0/22 patients in BroADen Phase 1b; dupilumab rates from LIBERTY AD trials",
        "caveat": "Cross-trial comparison. Different patient populations, trial designs, and treatment durations. No head-to-head data exists.",
        "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
      },
      {
        "claim": "Oral once-daily dosing vs biweekly injection",
        "comparator": "dupilumab (Dupixent)",
        "evidence_level": "head_to_head",
        "supporting_data": "KT-621 is oral QD; dupilumab is 300mg SC Q2W",
        "caveat": null,
        "source": {"id": "kymr_corporate_2026", "slide": 12, "verified": false}
      },
      {
        "claim": "TARC reduction in line with dupilumab at week 4",
        "comparator": "dupilumab (Dupixent)",
        "evidence_level": "cross_trial",
        "supporting_data": "KT-621 -74% median TARC (baseline ‚â•1,600 pg/mL) vs published dupilumab week 4 TARC reduction",
        "caveat": "Cross-trial comparison. TARC subgroup defined as baseline ‚â•1,600 pg/mL (lower bound 95% CI of median from SOLO1-2).",
        "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
      },
      {
        "claim": "Eotaxin-3 reduction numerically exceeded dupilumab even at 52 weeks",
        "comparator": "dupilumab (Dupixent)",
        "evidence_level": "cross_trial",
        "supporting_data": "KT-621 -73% median Eotaxin-3 at 200mg (Day 29) vs published dupilumab data in asthma and CRSwNP at 52 weeks",
        "caveat": "Cross-trial comparison across different indications (AD vs asthma/CRSwNP) and different timepoints (4 weeks vs 52 weeks). Particularly unreliable comparison.",
        "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
      }
    ]
  },
  "clinical_data": {
    "trials": [
      {
        "name": "BroADen Phase 1b",
        "nct_id": null,
        "phase": "Phase 1b",
        "status": "Completed",
        "design": "Open-label, single-arm, two sequential dose cohorts",
        "enrollment": "N=22",
        "arms": [
          {
            "name": "KT-621 100mg",
            "dose": "100mg QD",
            "n": 10
          },
          {
            "name": "KT-621 200mg",
            "dose": "200mg QD",
            "n": 12
          }
        ],
        "baseline_characteristics": {
          "mean_age": null,
          "disease_severity": "Mean baseline EASI ~25",
          "prior_therapy": "~23% prior biologics (dupilumab and/or tralokinumab)",
          "comorbidities": "~46% comorbid asthma or allergic rhinitis",
          "other": {
            "dose_groups_balanced": "Generally well-balanced for gender, age, race, vIGA-AD, EASI, PP-NRS"
          },
          "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
        },
        "primary_endpoint": {
          "name": "Safety and tolerability + STAT6 degradation",
          "definition": "Safety and tolerability of KT-621; demonstration of robust STAT6 degradation in blood and skin resulting in dupilumab-like Type 2 biomarker reductions",
          "timepoint": "Day 29"
        },
        "secondary_endpoints": [
          {
            "name": "EASI change from baseline",
            "definition": "Percent change in Eczema Area and Severity Index from baseline",
            "timepoint": "Day 29"
          },
          {
            "name": "Peak Pruritus NRS",
            "definition": "Percent change in Peak Pruritus Numerical Rating Scale from baseline",
            "timepoint": "Day 29"
          },
          {
            "name": "vIGA-AD response",
            "definition": "Proportion achieving score of 0 or 1 with ‚â•2-point improvement",
            "timepoint": "Day 29"
          },
          {
            "name": "SCORAD",
            "definition": "Percent change in SCORing Atopic Dermatitis Index from baseline",
            "timepoint": "Day 29"
          }
        ],
        "efficacy_results": {
          "stat6_degradation_blood": "98% median (both doses)",
          "stat6_degradation_skin": "94% median (both doses)",
          "easi_change": "-63% mean from baseline (all patients)",
          "easi_50": "76% of patients",
          "easi_75": "29% of patients",
          "viga_ad_response": "19% of patients",
          "pp_nrs_change": "-40% mean (all patients)",
          "scorad_total": "-48% mean (all patients)",
          "scorad_sleeplessness": "-76% mean (all patients)",
          "scorad_itch": "-44% mean (all patients)"
        },
        "efficacy_by_dose": {
          "100mg": {
            "n": 10,
            "easi_change": "-62% mean",
            "easi_50": "67%",
            "easi_75": "33%",
            "viga_ad_response": "22%",
            "pp_nrs_change": "-47% mean",
            "scorad_total": "-52% mean",
            "scorad_sleeplessness": "-72% mean",
            "scorad_itch": "-40% mean",
            "tarc_reduction": "-48% median",
            "eotaxin_3_reduction": "-62% median",
            "ige_reduction": "-5% median",
            "il_31_reduction": "-56% median",
            "feno_reduction": "-25% median",
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          },
          "200mg": {
            "n": 12,
            "easi_change": "-63% mean",
            "easi_50": "83%",
            "easi_75": "25%",
            "viga_ad_response": "17%",
            "pp_nrs_change": "-35% mean",
            "scorad_total": "-46% mean",
            "scorad_sleeplessness": "-78% mean",
            "scorad_itch": "-47% mean",
            "tarc_reduction": "-55% median",
            "eotaxin_3_reduction": "-73% median",
            "ige_reduction": "-14% median",
            "il_31_reduction": "-54% median",
            "feno_reduction": "-33% median",
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          }
        },
        "subgroup_analyses": [
          {
            "subgroup": "Patients with comorbid asthma",
            "n": 4,
            "results": {
              "feno_reduction": "-56% median",
              "acq_5_change": "-1.2 mean (100% responder rate at ‚â•0.5-point improvement)"
            },
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          },
          {
            "subgroup": "Patients with comorbid allergic rhinitis ‚Äî TNSS",
            "n": 7,
            "results": {
              "tnss": "meaningful improvements with notable responder rates (‚â•0.5-point improvement); no specific values reported"
            },
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          },
          {
            "subgroup": "Patients with comorbid allergic rhinitis ‚Äî RQLQ",
            "n": 6,
            "results": {
              "rqlq": "meaningful improvements with notable responder rates (‚â•0.5-point improvement); no specific values reported"
            },
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          },
          {
            "subgroup": "Patients with baseline TARC ‚â•1,600 pg/mL",
            "n": null,
            "results": {
              "tarc_reduction": "-74% median at Day 29"
            },
            "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
          }
        ],
        "safety": {
          "serious_adverse_events": "0%",
          "discontinuations_due_to_ae": "0%",
          "deaths": "0",
          "notable_aes": {
            "conjunctivitis": "0%",
            "herpes_infections": "0%",
            "arthralgias": "0%",
            "related_teaes": "0%"
          }
        },
        "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
      }
    ],
    "efficacy_summary": "KT-621 achieved near-complete STAT6 degradation in blood (98%) and skin (94%) at both 100mg and 200mg with meaningful improvements in eczema severity (EASI -63%), itch (PP-NRS -40%), and quality of life (SCORAD -48%). Results were generally consistent across dose groups, baseline severity levels, and prior biologic use. Rapid onset by Day 8.",
    "safety_summary": "Clean safety profile across both dose groups. No SAEs, no severe AEs, no related TEAEs, no discontinuations, no conjunctivitis, no herpes infections, no arthralgias, no clinically relevant changes in vitals, labs, or ECGs."
  },
  "biomarkers": {
    "tarc": {
      "change": "-74% median (patients with baseline ‚â•1,600 pg/mL); -48%/-55% median for 100mg/200mg across all patients",
      "by_dose": {
        "100mg": "-48% median (all patients)",
        "200mg": "-55% median (all patients)"
      },
      "context": "Validated biomarker of Type 2 inflammation. Reductions highly associated with baseline TARC levels. In patients with baseline TARC comparable to dupilumab studies (‚â•1,600 pg/mL), median reduction was 74%, in line with published dupilumab week 4 results.",
      "is_first_known_demonstration": false,
      "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
    },
    "eotaxin_3": {
      "change": "-62%/-73% median for 100mg/200mg",
      "by_dose": {
        "100mg": "-62% median",
        "200mg": "-73% median"
      },
      "context": "Highly specific downstream cytokine of IL-4/IL-13 pathway. 200mg result numerically exceeded published dupilumab data in asthma and CRSwNP at 52 weeks.",
      "is_first_known_demonstration": false,
      "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
    },
    "il_31": {
      "change": "-56%/-54% median for 100mg/200mg",
      "by_dose": {
        "100mg": "-56% median",
        "200mg": "-54% median"
      },
      "context": "Validated Type 2 biomarker linked to pruritus in AD. First known demonstration in AD patients of reduction in blood IL-31 levels with IL-4/13 pathway blockade.",
      "is_first_known_demonstration": true,
      "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
    },
    "ige": {
      "change": "-5%/-14% median for 100mg/200mg",
      "by_dose": {
        "100mg": "-5% median",
        "200mg": "-14% median"
      },
      "context": "Long half-life biomarker; gradual reduction expected and observed. Comparable to dupilumab at week 4.",
      "is_first_known_demonstration": false,
      "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
    },
    "feno": {
      "change": "-25%/-33% median for 100mg/200mg (all AD patients); -56% median in comorbid asthma subgroup",
      "by_dose": {
        "100mg": "-25% median",
        "200mg": "-33% median"
      },
      "context": "Validated biomarker of Type 2 lung inflammation. First known demonstration of FeNO reduction in AD patients, providing initial proof of concept for KT-621 inhibition of Type 2 inflammation in lungs.",
      "is_first_known_demonstration": true,
      "source": {"id": "kymr_press_release_2025", "slide": null, "verified": false}
    }
  },
  "ip_landscape": null
}
```

---

## 8. Extraction Workflow

When extracting from a new source document:

1. **Identify the source:** Create a source entry using convention `{ticker}_{doctype}_{year}`
2. **Check for existing data:** If an asset file already exists, this is a MERGE operation ‚Äî follow the merge rules in Section 2.
3. **Extract company.json first:** Company overview, pipeline, financials, catalysts, management track record
4. **Extract one asset.json per clinical program:** Start with the lead asset
5. **For each asset, extract in this order:**
   a. Asset basics + target + mechanism
   b. Regulatory designations
   c. Partnership economics (or set to null if wholly-owned)
   d. Pharmacology / PK / dose-response
   e. Clinical trial data (with baseline characteristics and dose-level breakdowns)
   f. Subgroup analyses
   g. Biomarkers (with dose-level breakdowns)
   h. Differentiation claims (tag every one with evidence level)
   i. Competitive landscape
   j. IP landscape (or null if not in source)
   k. Market opportunity
   l. Catalysts
   m. Investment analysis (editorial)
6. **Cite every factual claim:** Add source objects with slide/page numbers as you go
7. **Self-check before outputting:**
   - Does every clinical number have a source reference?
   - Are all efficacy/safety values flat strings (not nested objects)?
   - Did I use `null` for anything not in the document (vs making something up)?
   - Are required fields filled: `company.one_liner`, `target.name`, `target.biology.simple_explanation`?
   - Does every differentiation claim have an `evidence_level`?
   - Are cross-trial comparisons in `differentiation_claims`, NOT embedded in safety/efficacy fields?
   - Are bull/bear points linked to specific data via `evidence_refs`?
   - Are qualitative descriptions flagged as qualitative (not passed off as data)?
   - **When dose-level data exists in the source, is it captured in `efficacy_by_dose` and biomarker `by_dose`?**
   - **Are baseline characteristics populated for every trial?**
   - **Are all sources registered in `_metadata.sources`?**
   - **If merging, are conflicts flagged with `_conflict` and refinements noted with `_refined_from`?**
8. **Flag uncertainty:** If a data point is ambiguous, add a `"_note"` field explaining the ambiguity

---

## 9. What NOT to Extract

- Slide titles and section headers (unless they contain data)
- Forward-looking statements without supporting data ("We believe we can achieve...")
- Boilerplate legal disclaimers
- Full management biographies (extract only relevant track record: prior approvals, exits, TA experience)
- Stock performance charts
- General industry statistics not specific to the company's opportunity

---

## 10. Companies Extracted

| Ticker | Company | Assets | Status |
|--------|---------|--------|--------|
| KYMR | Kymera Therapeutics | kt621, kt579, kt485 | ‚úÖ Live ‚Äî gold standard (needs v2.2 retrofit) |
| NUVL | Nuvalent | zidesamtinib, neladalkib, nvl330 | ‚úÖ Live (needs v2.2 retrofit) |
| ARGX | argenx | efgartigimod, empasiprubart | üîÑ Needs re-extract |
| CDTX | Cidara (acquired by Merck) | rezafungin | ‚úÖ Extracted (needs v2.2 retrofit) |
| EWTX | Edgewise | ‚Äî | ‚è≥ Pending |
| INSM | Insmed | ‚Äî | ‚è≥ Pending |
| ACLX | Arcellx | ‚Äî | ‚è≥ Pending |

---

## Changelog

- **v1.0** (2026-02-06): Initial version with schema, source references, quality standards, KYMR example
- **v1.1** (2026-02-06): Added regulatory designations, differentiation claims with evidence levels, pharmacology/PK section, partnership economics, IP landscape, management track record, qualitative data handling rules, bull/bear evidence_refs, secondary endpoints, deaths in safety, evidence_level on competitive comparisons. Bumped schema version to 2.1. Fixed cross-trial comparison leaking into safety fields. Split gold standard example guidance for context window management.
- **v1.2** (2026-02-06): Multi-source support ‚Äî `_metadata.sources` array replaces single `source_id`. Added merge rules (granularity wins, recent wins, additive new content, `_conflict` flagging, `_refined_from` tracking). Added `baseline_characteristics` to trial schema. Added `efficacy_by_dose` for dose-level efficacy breakdowns. Added `subgroup_analyses` array to trials. Added `by_dose` and `is_first_known_demonstration` to biomarkers. Expanded KYMR gold standard example with full BroADen press release data showing multi-source, dose-level, and subgroup extraction. Bumped schema version to 2.2.
